Results 161 to 170 of about 1,518 (207)

Laser-assisted drug delivery of topical ruxolitinib for treatment-refractory stable nonsegmental vitiligo: A case analyzed using noninvasive imaging modalities. [PDF]

JAAD Case Rep
Rafiq B, Pathak GN, Musolff N, Tchack M, Rao BK.   +4 more
europepmc   +1 more source

Integrated Safety Analysis of Ruxolitinib Cream: Data From 20 Clinical Studies in Inflammatory Dermatologic Conditions

Karen Miller, Christopher G. Bunick, Khaled Ezzedine, Lawrence F. Eichenfield, Robert Bissonnette, Thierry Passeron, Daniel Sturm, Haobo Ren, Yun Su, David Rosmarin   +9 more
openalex   +2 more sources

Case Report: Successful treatment of steroid-refractory graft-vs.-host disease following bilateral lung transplantation. [PDF]

Front Transplant
McCormick BJ, Rusanov V, Tao Z, Kaleekal T, Wille K, Espinoza-Gutarra MR.   +5 more
europepmc   +1 more source

Real-World Use of Topical Ruxolitinib in Vitiligo: Retrospective Cross-Sectional Mixed Methods Infodemiology Study of the r/Vitiligo Subreddit.

J Med Internet Res
Kirchberger MC, Berking C, Eisenried A.
europepmc   +1 more source

Ribociclib-induced Vitiligo in a Patient with Metastatic Breast Cancer [PDF]

Conde, Geena, Pascucci, Anabella
core  

Some of the next articles are maybe not open access.

Related searches:

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

New England Journal of Medicine, 2022
Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo.We conducted two phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1 ...
Thierry Passeron
exaly   +5 more sources

Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream

JAMA Dermatology, 2023
This case report describes a 46-year-old woman who presented with numerous monomorphic, mildly erythematous, and skin-colored smooth indurated papules that coalesced into plaques that involved the upper and lower eyelids, forehead, medial cheeks, cutaneous lips, and chin.
Natalie C, Gorham, Jonathan, Jacobs, Sean Z, Wu   +2 more
openaire   +2 more sources

Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis

Expert Review of Clinical Immunology, 2022
Atopic dermatitis (AD) is a chronic, recurrent, itchy inflammatory skin disease with a vast influence on a patient's quality of life (QoL). Mild-moderate AD was classically managed with the use of topical corticosteroid (TCS) and calcineurin inhibitors (TCI). It was proven that the JAK pathway plays an important role in the development of AD.
Piotr K Krajewski, Jacek C Szepietowski
openaire   +3 more sources